LTZ Named 2026 "Immunology Innovation of the Year" by BioTech Breakthrough

Recognition Shines a Spotlight on LTZ's Proprietary Myeloid Engager Platform

REDWOOD CITY, California – November 5, 2026 – LTZ Therapeutics (LTZ), a clinical-stage, immunotherapy-focused biotechnology company, today announced it has been selected as the winner of the "Immunology Innovation of the Year" award in the annual BioTech Breakthrough Awards program.

The BioTech Breakthrough Awards aim to recognize the top companies and solutions driving innovation across the life sciences and biotechnology sectors. To view the complete list of 2026 winners, visit the BioTech Breakthrough Awards website.

"Anchored by an experienced team, we're honored to receive this recognition, acknowledging the potential of our Myeloid Engager Platform and its tangible clinical impact for patients," said Robert Li, Ph.D., founder and chief executive officer of LTZ. "We are building strong momentum across our pipeline, and the support from our partners validates our innovative immunotherapies in development, which are designed to harness myeloid biology and address significant unmet medical needs."

Preclinical and early clinical data for LTZ-301 and LTZ-232 demonstrate promising therapeutic potential, suggesting broad applicability of LTZ's Universal Myeloid Cell Engager (U-MCE™) Platform across hard-to-treat cancers (liquid and solid) and autoimmune diseases.

About LTZ's Scientific Approach

LTZ's approach focuses on the fusion of reverse translational science, with a deep understanding of Tumor Microenvironment (TME) biology—especially myeloid biology. Macrophages are one of the most prevalent immune cell populations in the TME of many hematologic and solid tumors. Therefore, effectively engaging and activating macrophages to kill cancer cells offers significant therapeutic potential for patients. LTZ is developing its own U-MCE™ Platform to broadly enhance the phagocytic function of monocytes and macrophages to foster anti-tumor immunity. Additionally, LTZ is exploring the potential therapeutic benefit of its platform for other non-oncology diseases.

About LTZ

LTZ Therapeutics is a clinical-stage, immunotherapy-focused biotechnology company pursuing the development of novel therapies, with the company's Universal Myeloid Cell Engager (U-MCE™) Platform, to improve clinical outcomes in patients with oncology and autoimmune diseases. With headquarters in Redwood City, California and additional operations in Shenzhen, China, LTZ is dedicated to developing myeloid engager immunotherapies for broad disease indications. For more information, please visit https://www.ltztherapeutics.com/.